Anti-angiogenic properties of chemopreventive drugs: fenretinide as a prototype.
Several cancer chemopreventive agents have been demonstrated to exert antiangiogenic effects. Blocking tumor angiogenesis, a process critical for tumor mass expansion and metastasis, represents an intriguing approach not only to cancer therapy, but also to cancer chemoprevention. We found that angiogenesis is a common and key target of many chemopreventive molecules, where they most likely suppress the angiogenic switch in premalignant tumors, a concept we termed "angioprevention." In this manuscript we use as an example the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR), a molecule with confirmed clinical applications in breast cancer adjuvant therapy to prevent cancer recurrence and under evaluation in neuroblastoma and glioblastoma treatment.
Sogno
Ilaria
I
IRCCS MultiMedica, Oncology Research, Milan, Italy.
Venè
Roberta
R
Sapienza
Cristina
C
Ferrari
Nicoletta
N
Tosetti
Francesca
F
Albini
Adriana
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017313:Fenretinide / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*
D000970:Antineoplastic Agents; D017313:Fenretinide